Belite Bio (BLTE) Other Non Operating Income (2024 - 2025)

Belite Bio (BLTE) posted quarterly Other Non Operating Income of -$302000.0 for Q4 2025, down 322.06% year-over-year from $136000.0 in Q4 2024, and down 322.06% on a QoQ basis from $136000.0 in Q4 2024.

Belite Bio (BLTE) Other Non Operating Income (2024 - 2025) Analysis & Trends

Belite Bio (BLTE) has reported Other Non Operating Income for 2 consecutive years, with -$302000.0 the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn -
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn
9 Revolution Medicines 37.15 Bn 37.15 Bn -
10 Belite Bio 96.77 Mn 96.77 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -302,000.00
Dec 31, 2024 136,000.00